Undetectable bcr-abl rearrangements in some CML patients are due to a deletion mutation in the bcr gene.
Most patients with chronic myelogenous leukemia (CML) have Philadelphia (Ph) chromosome. Breakpoints on chromosome 22 in CML occur in a small region designated as the breakpoint cluster region (bcr). More than 90 percent of CML patients have breakpoints in the bcr; the remaining patients had no detectable rearrangement. In our study, a commercially available 1.2 kb HindIII-BglII (1.2 HBg) bcr probe was used to locate breakpoints in the bcr, which were found in 22 of 24 patients. Furthermore, using a probe upstream from the 1.2 HBg probe, rearranged bands were clearly detected in the two patients in whom no extra bands had been found with the 1.2 HBg probe. These results strongly suggest that these two patients carry a deletion at the acr-abl recombination point encompassing the area of the 1.2 HBg probe. Therefore, in our series, all CML patients eventually had breakpoints in the bcr, and the involvement of rearrangement was demonstrated to be highly specific for CML. Our data indicate that hybridization of CML cellular DNA with several bcr probes is important in examining accurately the frequency of bcr-abl rearrangements in CML, as some cases contain a deletion within the region.
Hirosawa
S
S
First Department of Medicine, Tokyo Medical and Dental University, Japan.
Aoki
N
N
Matsushime
H
H
Shibuya
M
M
D002869:Chromosome Aberrations / Q000097:blood / Q000235:genetics*; D002872:Chromosome Deletion; D025063:Chromosome Disorders; D002892:Chromosomes, Human, Pair 22; D003001:Cloning, Molecular; D004262:DNA Restriction Enzymes; D006801:Humans; D007951:Leukemia, Myeloid / Q000097:blood / Q000235:genetics*; D009154:Mutation; D009710:Nucleotide Mapping; D009857:Oncogenes; D011995:Recombination, Genetic
D004262:DNA Restriction Enzymes